BACKGROUND: Probiotics are the most frequently prescribed treatment for children hospitalized with diarrhea in Vietnam. We were uncertain of the benefits of probiotics for the treatment of acute watery diarrhea in Vietnamese children. METHODS: We conducted a double-blind, placebo-controlled, randomized trial of children hospitalized with acute watery diarrhea in Vietnam. Children meeting the inclusion criteria (acute watery diarrhea) were randomized to receive either 2 daily oral doses of 2 × 10 CFUs of a local probiotic containing Lactobacillus acidophilus or placebo for 5 days as an adjunct to standard of care. The primary end point was time from the first dose of study medication to the start of the first 24-hour period without diarrhea. Secondary outcomes included the total duration of diarrhea and hospitalization, daily stool frequency, treatment failure, daily fecal concentrations of rotavirus and norovirus, and Lactobacillus colonization. RESULTS:One hundred and fifty children were randomized into each study group. The median time from the first dose of study medication to the start of the first 24-hour diarrhea-free period was 43 hours (interquartile range, 15-66 hours) in the placebo group and 35 hours (interquartile range, 20-68 hours) in the probiotic group (acceleration factor 1.09 [95% confidence interval, 0.78-1.51]; P = 0.62). There was also no evidence that probiotic treatment was efficacious in any of the predefined subgroups nor significantly associated with any secondary end point. CONCLUSIONS: This was a large double-blind, placebo-controlled trial in which the probiotic underwent longitudinal quality control. We found under these conditions that L. acidophilus was not beneficial in treating children with acute watery diarrhea.
RCT Entities:
BACKGROUND: Probiotics are the most frequently prescribed treatment for children hospitalized with diarrhea in Vietnam. We were uncertain of the benefits of probiotics for the treatment of acute watery diarrhea in Vietnamese children. METHODS: We conducted a double-blind, placebo-controlled, randomized trial of children hospitalized with acute watery diarrhea in Vietnam. Children meeting the inclusion criteria (acute watery diarrhea) were randomized to receive either 2 daily oral doses of 2 × 10 CFUs of a local probiotic containing Lactobacillus acidophilus or placebo for 5 days as an adjunct to standard of care. The primary end point was time from the first dose of study medication to the start of the first 24-hour period without diarrhea. Secondary outcomes included the total duration of diarrhea and hospitalization, daily stool frequency, treatment failure, daily fecal concentrations of rotavirus and norovirus, and Lactobacillus colonization. RESULTS: One hundred and fifty children were randomized into each study group. The median time from the first dose of study medication to the start of the first 24-hour diarrhea-free period was 43 hours (interquartile range, 15-66 hours) in the placebo group and 35 hours (interquartile range, 20-68 hours) in the probiotic group (acceleration factor 1.09 [95% confidence interval, 0.78-1.51]; P = 0.62). There was also no evidence that probiotic treatment was efficacious in any of the predefined subgroups nor significantly associated with any secondary end point. CONCLUSIONS: This was a large double-blind, placebo-controlled trial in which the probiotic underwent longitudinal quality control. We found under these conditions that L. acidophilus was not beneficial in treating children with acute watery diarrhea.
Authors: Mary Ellen Sanders; James T Heimbach; Bruno Pot; Daniel J Tancredi; Irene Lenoir-Wijnkoop; Anu Lähteenmäki-Uutela; Miguel Gueimonde; Silvia Bañares Journal: Gut Microbes Date: 2011-05-01
Authors: Do Kyung Lee; Jae Eun Park; Min Ji Kim; Jae Goo Seo; Ji Hyuk Lee; Nam Joo Ha Journal: Clin Res Hepatol Gastroenterol Date: 2014-11-12 Impact factor: 2.947
Authors: Li Liu; Hope L Johnson; Simon Cousens; Jamie Perin; Susana Scott; Joy E Lawn; Igor Rudan; Harry Campbell; Richard Cibulskis; Mengying Li; Colin Mathers; Robert E Black Journal: Lancet Date: 2012-05-11 Impact factor: 79.321
Authors: Hao Chung The; Maia A Rabaa; Duy Pham Thanh; Niall De Lappe; Martin Cormican; Mary Valcanis; Benjamin P Howden; Sonam Wangchuk; Ladaporn Bodhidatta; Carl J Mason; To Nguyen Thi Nguyen; Duong Vu Thuy; Corinne N Thompson; Nguyen Phu Huong Lan; Phat Voong Vinh; Tuyen Ha Thanh; Paul Turner; Poda Sar; Guy Thwaites; Nicholas R Thomson; Kathryn E Holt; Stephen Baker Journal: PLoS Med Date: 2016-08-02 Impact factor: 11.069
Authors: Marion-Eliëtte Kolader; Ha Vinh; Pham Thi Ngoc Tuyet; Corinne Thompson; Marcel Wolbers; Laura Merson; James I Campbell; Tran Thi Ngoc Dung; Ha Manh Tuan; Nguyen Van Vinh Chau; Jeremy Farrar; H Rogier van Doorn; Stephen Baker Journal: Trials Date: 2013-01-28 Impact factor: 2.279
Authors: Stephen B Freedman; Yaron Finkelstein; Xiao Li Pang; Linda Chui; Phillip I Tarr; John M VanBuren; Cody Olsen; Bonita E Lee; Carla A Hall-Moore; Robert Sapien; Karen O'Connell; Adam C Levine; Naveen Poonai; Cindy Roskind; Suzanne Schuh; Alexander Rogers; Seema Bhatt; Serge Gouin; Prashant Mahajan; Cheryl Vance; Katrina Hurley; Elizabeth C Powell; Ken J Farion; David Schnadower Journal: Clin Infect Dis Date: 2022-08-24 Impact factor: 20.999
Authors: Shelui Collinson; Andrew Deans; April Padua-Zamora; Germana V Gregorio; Chao Li; Leonila F Dans; Stephen J Allen Journal: Cochrane Database Syst Rev Date: 2020-12-08
Authors: Teruomi Tsukahara; Anri Fujimori; Yuka Misawa; Hirotsugu Oda; Koji Yamauchi; Fumiaki Abe; Tetsuo Nomiyama Journal: Int J Environ Res Public Health Date: 2020-04-07 Impact factor: 3.390